𝐔𝐥𝐭𝐨𝐦𝐢𝐫𝐢𝐬 𝐃𝐫𝐮𝐠 𝐌𝐚𝐫𝐤𝐞𝐭 𝐆𝐫𝐨𝐰𝐭𝐡 Innovations in Rare Disease Biologics

aggiunto articolo blog Altre informazioni

2026-05-18 06:18:50 -

The Ultomiris Drug Market is experiencing significant growth due to the increasing prevalence of rare autoimmune and hematologic disorders, rising awareness about complement-mediated diseases, and advancements in biologic therapies. Ultomiris (ravulizumab), a long-acting complement C5 inhibitor, has emerged as a breakthrough treatment for several life-threatening conditions, driving...

0 Commenti 0 Condivisioni 77 Visualizzazioni